iShares MSCI Australia ETF vs Liquidia Corporation Common Stock — how do they compare? iShares MSCI Australia ETF trades at $28.76 (market cap $1.19B), while Liquidia Corporation Common Stock trades at $33.56 (market cap $3.04B). The key difference: Liquidia Corporation Common Stock is far larger — about 2.6× iShares MSCI Australia ETF's market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Liquidia Corporation Common Stock for 0 Days on average.
| EWA | LQDA | |
|---|---|---|
Market Cap | $1.19B | $3.04B |
Volume | 5,792,656 | 21,111,778 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $91.03 |
52-Week Low | $24.95 | $22.02 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $2.94B |
Signals from Pluang's Aura AI — not financial advice
EWA (iShares MSCI Australia ETF) trades at $28.675, down 0.33% with bearish technical signals from moving averages and mixed oscillators. The ETF faces headwinds from Australian market volatility and inflation concerns, though some analysts see upside potential from commodity exposure. Recent institutional activity shows mixed positioning with Squarepoint Ops reducing holdings while Cetera Investment Advisers increased exposure.
The outlook remains cautious given technical weakness and macroeconomic pressures, though the commodity-focused strategy offers potential upside if raw material prices support Australia's export economy. Key risks include persistent inflation, monetary policy tightening, and global economic uncertainty affecting commodity demand.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →